ARCHIVES

Phase III Xtandi Trial Meets Primary Endpoints Of Progression-Free and Overall Survival

This article is from The Cancer Letter archive.

Vol. 36 No. 11 | November 29, 2013

Download PDF Visit The Full Archive

Related Articles

DCPC Board OKS P01 Grants Program In Nutrition Research

March 11, 1994

In Brief: Simone Named New Director At St. Jude; Schein To Leave Georgetown For Job At Smith-Kline

September 16, 1983

Senate Appropriations Report Language On NCI, NIH Budgets

September 20, 1996

Pharmacogenomics May Lead To Individualized Treatment

June 25, 2004

Personal letters: mixed reviews of Donald Pinkel’s article on Childhood Lymphocytic Leukemia

May 6, 2021

Robert Cook-Deegan’s Viewers’ Guide To the Super Bowl of Gene Patent Cases

March 14, 2014